Pharmacokinetics of Na2B12H11SH (BSH) in patients with malignant brain tumours as prerequisite for a phase I clinical trial of boron neutron capture

Research output: Contribution to journalArticle

Abstract

The disposition of Na2B12H11SH (BSH) in patients with malignant glioma has been investigated, in preparation for a Phase I clinical trial of boron neutron capture therapy. BSH was found to possess a linear disposition over the dosage interval investigated (up to 75 mg/kg). A bi-phasic blood pharmacokinetics was observed. Tumour-to-blood ratios showed variations between patients between 0.08 and 5.1. The data allow the definition of amount of BSH and timing of infusion for a Phase I clinical trial protocol.

Details

Authors
  • D Gabel
  • D Preusse
  • D Haritz
  • F Grochulla
  • K Haselsberger
  • H Fankhauser
  • Crister Ceberg
  • H D Peters
  • U Klotz
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Radiology, Nuclear Medicine and Medical Imaging

Keywords

  • Boron neutron capture therapy, glioma, BSH
Original languageEnglish
Pages (from-to)606-612
JournalActa Neurochirurgica
Volume139
Issue number7
Publication statusPublished - 1997
Publication categoryResearch
Peer-reviewedYes